Second-degree Burn Clinical Trial
Official title:
Pirfenidone and Its Efficacy in Wound Re-Epithelization in Patients With Second-Degree Burns: A Proof-of-Concept Randomized Controlled Trial
Burn patients which skin has been lost a rapid growth of the skin is a foremost in their treatment. Due to the injury, burn patients undergo a systemic inflammation that helps the skin heal faster. However, several studies have shown that this inflammation increases the levels of several inflammatory molecules that impairs skin growing, which further delays the recovery of burn patients. As such, by inhibiting these inflammatory molecules with the administration of a medication called pirfenidone burn patients might present faster rates of skin growth and recovery. Thus, patients suffering from a burn injury will be recruited at the emergency department of the Hospital University in Monterrey Mexico. Afterward, patients will be randomized to either receive pirfenidone 600 mg orally once per day or usual care consisting of covering the wound with hydrocolloid dressings. To assess the amount of newly growth skin investigators will take a small piece of the skin to further evaluate it through a microscope.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02108535 -
Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns
|
Phase 4 | |
| Withdrawn |
NCT04149808 -
Mepilex Ag vs. Xeroform in Pediatric Patients That Sustain Partial Thickness Burn Injury
|
N/A | |
| Recruiting |
NCT03048188 -
Manuka Honey in Second- and Grafted Third-degree Burns
|
N/A |